doxorubicin induced cardiomyopathy
doxorubicin induced cardiomyopathy
Explore linked clinical trials. Standard reference: MONDO:00230062 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, doxorubicin induced cardiomyopathy, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-04-17 | NCT06427226 | |
| Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, doxorubicin induced cardiomyopathy, neoplasm, skin disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-01-29 | NCT07370506 |